DeLong Mark Jeffrey 4

What Happened Mark DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals (APLS), sold 1,334 shares in an open-market transaction on January 20, 2026, at $19.79 per share, generating proceeds of approximately $26,404. This was a sale (not a purchase) and appears to be a routine disposition tied to tax obligations rather than a directional investment bet.

Key Details

• Transaction date and price: 2026-01-20, 1,334 shares sold at $19.79/share.
• Total proceeds: about $26,404.
• Shares owned after transaction: not reported in this Form 4.
• Footnote: Sale made to cover tax withholding on Restricted Stock Units (RSUs) released on January 16, 2026 (tax-withholding sale).
• Filing: Form 4 filed 2026-01-21; no late filing flag indicated in the provided record.
• Transaction codes: S = Sale; F (footnote) = tax withholding.

Context The sale was to satisfy tax withholding on recently vested RSUs — a common, administrative reason insiders sell shares and not necessarily a signal about the insider's view of the company's prospects. Purchases typically carry more weight for assessing insider sentiment; this reported activity is primarily procedural.